Noradrenaline induces peripheral antinociception by endogenous opioid release

Area of Science:

• Neuroscience
• Pharmacology
• Pain Research

Background:

• Noradrenaline (NA) plays a role in pain modulation via primary afferent nociceptors.
• Inflammation can alter the noradrenergic system, potentially contributing to peripheral antinociception.
• The specific opioid receptor subtypes involved in noradrenaline-induced peripheral antinociception remain to be fully elucidated.

Purpose of the Study:

• To investigate noradrenaline-induced peripheral antinociception in a non-inflammatory pain model.
• To determine which opioid receptor subtypes mediate this antinociceptive effect.

Main Methods:

• Hyperalgesia was induced using prostaglandin E2 (PGE2) in Wistar rats.
• Noradrenaline (NA) was administered intraplantarly, alone and with various receptor antagonists (yohimbine, prazosin, propranolol, clocinnamox, naltrindole, nor-binaltorfimina).
• The enkephalinase inhibitor bestatin was also tested prior to low-dose NA administration.

Main Results:

• Intraplantar NA induced peripheral antinociception against PGE2-induced hyperalgesia.
• This effect was dose-dependently reversed by antagonists for alpha2, alpha1, beta, mu, and delta adrenoceptors.
• Kappa opioid receptor antagonism did not affect NA's antinociceptive action.
• Bestatin enhanced the antinociceptive effects of low-dose NA.

Conclusions:

• Noradrenaline (NA) induces peripheral antinociception via alpha1 and beta adrenoceptors in the absence of inflammation.
• This effect involves the release of endogenous opioids that act on mu and delta opioid receptors.
• Alpha2 adrenoceptors are also involved in this non-inflammatory pain pathway.